Monopar Therapeutics (MNPR) Competitors $75.90 -0.73 (-0.95%) Closing price 09/29/2025 04:00 PM EasternExtended Trading$75.75 -0.15 (-0.20%) As of 04:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNPR vs. BHVN, EWTX, ARDX, SDGR, JANX, COGT, GPCR, ABCL, TLRY, and PHVSShould you be buying Monopar Therapeutics stock or one of its competitors? The main competitors of Monopar Therapeutics include Biohaven (BHVN), Edgewise Therapeutics (EWTX), Ardelyx (ARDX), Schrodinger (SDGR), Janux Therapeutics (JANX), Cogent Biosciences (COGT), Structure Therapeutics (GPCR), AbCellera Biologics (ABCL), Tilray Brands (TLRY), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry. Monopar Therapeutics vs. Its Competitors Biohaven Edgewise Therapeutics Ardelyx Schrodinger Janux Therapeutics Cogent Biosciences Structure Therapeutics AbCellera Biologics Tilray Brands Pharvaris Monopar Therapeutics (NASDAQ:MNPR) and Biohaven (NYSE:BHVN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment. Do analysts rate MNPR or BHVN? Monopar Therapeutics presently has a consensus target price of $86.22, suggesting a potential upside of 13.60%. Biohaven has a consensus target price of $48.85, suggesting a potential upside of 232.74%. Given Biohaven's stronger consensus rating and higher probable upside, analysts plainly believe Biohaven is more favorable than Monopar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monopar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00Biohaven 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 3 Strong Buy rating(s) 3.13 Which has more risk & volatility, MNPR or BHVN? Monopar Therapeutics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, Biohaven has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Do insiders & institutionals hold more shares of MNPR or BHVN? 1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 20.5% of Monopar Therapeutics shares are owned by company insiders. Comparatively, 14.6% of Biohaven shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is MNPR or BHVN more profitable? Monopar Therapeutics' return on equity of -41.76% beat Biohaven's return on equity.Company Net Margins Return on Equity Return on Assets Monopar TherapeuticsN/A -41.76% -39.49% Biohaven N/A -270.65%-143.70% Does the media favor MNPR or BHVN? In the previous week, Monopar Therapeutics had 25 more articles in the media than Biohaven. MarketBeat recorded 28 mentions for Monopar Therapeutics and 3 mentions for Biohaven. Biohaven's average media sentiment score of 1.20 beat Monopar Therapeutics' score of 0.77 indicating that Biohaven is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, MNPR or BHVN? Monopar Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonopar TherapeuticsN/AN/A-$15.59M-$3.33-22.79BiohavenN/AN/A-$846.42M-$7.66-1.92 SummaryMonopar Therapeutics and Biohaven tied by winning 7 of the 14 factors compared between the two stocks. Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MNPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNPR vs. The Competition Export to ExcelMetricMonopar TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$472.80M$3.11B$5.68B$10.37BDividend YieldN/A2.43%5.78%4.67%P/E Ratio-22.7921.6975.6326.39Price / SalesN/A256.11466.79201.98Price / CashN/A43.2725.6730.68Price / Book8.419.7213.136.40Net Income-$15.59M-$52.86M$3.29B$276.69M7 Day Performance12.16%2.40%1.37%0.12%1 Month Performance122.25%8.67%4.58%6.78%1 Year Performance1,026.11%19.51%70.10%26.72% Monopar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNPRMonopar Therapeutics2.5797 of 5 stars$75.90-1.0%$86.22+13.6%+1,021.1%$472.80MN/A-22.7910News CoverageAnalyst ForecastAnalyst RevisionGap UpBHVNBiohaven3.3539 of 5 stars$14.92+4.2%$50.07+235.7%-71.2%$1.51BN/A-1.95239EWTXEdgewise Therapeutics2.3498 of 5 stars$15.10+5.9%$40.55+168.5%-39.6%$1.50BN/A-9.7460ARDXArdelyx4.3678 of 5 stars$6.22+0.2%$11.70+88.1%-15.3%$1.50B$333.61M-27.0490SDGRSchrodinger3.1699 of 5 stars$19.72+1.4%$27.83+41.1%+6.9%$1.43B$207.54M-7.95790Positive NewsJANXJanux Therapeutics2.4422 of 5 stars$23.51+0.3%$78.31+233.1%-48.8%$1.41B$10.59M-13.0630COGTCogent Biosciences2.6042 of 5 stars$12.51+4.5%$20.00+59.9%+29.6%$1.36BN/A-7.0380GPCRStructure Therapeutics3.1959 of 5 stars$24.45+3.7%$68.67+180.8%-39.4%$1.36BN/A-23.29136Positive NewsABCLAbCellera Biologics3.0814 of 5 stars$4.83+7.1%$8.00+65.6%+86.6%$1.35B$28.83M-8.78500News CoveragePositive NewsTLRYTilray Brands1.1922 of 5 stars$1.20-0.8%$1.94+61.5%+6.3%$1.33B$821.31M-0.522,842Trending NewsOptions VolumeGap UpPHVSPharvaris2.4635 of 5 stars$24.99-1.5%$34.00+36.1%+30.9%$1.33BN/A-7.4430Positive News Related Companies and Tools Related Companies Biohaven Alternatives Edgewise Therapeutics Alternatives Ardelyx Alternatives Schrodinger Alternatives Janux Therapeutics Alternatives Cogent Biosciences Alternatives Structure Therapeutics Alternatives AbCellera Biologics Alternatives Tilray Brands Alternatives Pharvaris Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNPR) was last updated on 9/30/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredDefense Billions Flow Into Critical Minerals — Here’s Why Gold’s KeyWhat do missile defense systems and gold miners have in common? More than most investors realize. The Unite...The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MNPR Stock Alerts